Cultural science research on RNA editing for treatment of Huntington’s disease

Projekt: Forskning

Populärvetenskaplig beskrivning

Huntingtons sjukdom (HS) är en svår och ärftlig hjärnsjukdom som orsakar stort lidande för den drabbade och som leder till för tidig död. Idag finns endast symtomatisk behandling som är helt otillräcklig. Målsättningen med detta projekt är att utveckla en nymetoder för att bota HS med hjälp av virusbärare.Etiska och samhällsvetenskapliga aspekter av denna nya genterapibehandling görs.

Huntington?s disease (HD) is a hereditary neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin (htt) gene. Individuals with the mutant htt gene suffer throughout their adult life and die in agony at midlife. Available medication provides only minor symptomatic relief. There is therefore an urgent need for the development of effective treatments. Our aim is to develop a
completely novel and groundbreaking therapy based on an mRNA editing principle called trans-splicing, which will correct the mRNA
coding for the mutated htt protein to make wild type htt instead. Our chosen strategy to correct mutant htt into wild-type htt compared
to only reducing mutant htt may be critical as normal htt is essential for neuronal function. To develop and evaluate this therapy, we
will use unique cell models based on human cells and animal models expressing the entire human genomic region for the htt gene.
The therapeutic tool is an adeno-associated virus vector, which shows excellent safety for gene delivery in the brain. We will also
employ novel detection tools for quantification of mutant and corrected htt proteins and advanced magnetic resonance imaging and
spectroscopy techniques in both animals and HD patients using the state-of-the-art equipment at Lund University Bioimaging Center.
Relevant ethical and social aspects with respect to novel treatment strategies will be incorporated and taken into consideration at an
early stage in the project.
StatusPågående
Effective start/end date2013/01/012017/12/31

Participants